帕拉曼尼尔作为日本发作的一线单一治疗. 一个单一的中心真实世界的研究
Naoki Nakano1, Kouichiro Fujimoto2, Masaharu Miyauchi2
1Department of Neurosurgery, Kindai University School of Medicine Address, 377-2, Ohno-Higashi, Osaka-Sayama, 589-8511, Osaka, Japan. nnakano@med.kindai.ac.jp.
Acta neurologica Belgica
|August 17, 2025
概括
在日本的患者中,Perampanel (PER) 单一治疗显示出高疗效,77.8%的患者实现了无发作. 这项研究强调了PER作为各种发作类型的有效一线治疗方法,即使是低剂量.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
- 临床医学 临床医学
背景情况:
- 日本国家医疗保险于2020年1月开始覆盖Perampanel (PER) 单疗.
- 随后,PER单疗法作为该研究所的治疗选择被实施.
研究的目的:
- 为了评估Perampanel (PER) 单一治疗在日本患者中的疗效.
- 评估接受PER单一治疗的患者的治疗结果,包括发作率和无发作状态.
主要方法:
- 在2020年1月至2022年12月期间接受PER单一治疗的63名患者的回顾性研究.
- 评估发作率,无发作状态,患者人口统计,发作类型和病因.
- 对Perampanel剂量和不良反应的分析.
主要成果:
- 77.8%的患者 (49/63) 在佩拉曼尼尔单独治疗时实现了无.
- 在12.7% (25-49%的减少) 和6.3% (50-74%的减少) 的患者中观察到显著的发作减少.
- 平均每天2毫克的Perampanel剂量是有效的,没有因不良反应而停止治疗.
结论:
- 佩拉曼奈尔单一治疗对广泛的发作有效,特别是与大脑病变相关的发作.
- 有效的发作控制可以通过每日低剂量的Perampanel (每天2毫克) 来实现.
- 在日本,单疗法是治疗的有价值的选择.
相关概念视频
Antiepileptic Drugs: GABAergic Pathway Potentiators
646
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
646
Epilepsy and Seizures: Overview
280
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
280
Antiepileptic Drugs: Potassium Channel Activators
276
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
276
Seizures: Classification
589
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
589
Antiepileptic Drugs: Glutamate Antagonists
516
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
516
Electroconvulsive Therapy
189
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
189


